Insurance Coverage for Newer DORAs: What You'll Actually Pay in 2025

What Are DORAs and Why Do Insurers Treat Them Differently?

Dual orexin receptor antagonists block orexin-1 and orexin-2 receptors in the brain, reducing wakefulness drive rather than broadly suppressing CNS activity. The FDA approved suvorexant (Belsomra) in 2014, lemborexant (Dayvigo) in 2019, and daridorexant (Quviviq) in January 2022 [1, 2, 3]. All three carry a Schedule IV classification under the Controlled Substances Act, the same schedule as zolpidem, yet they have a pharmacologically distinct mechanism that the prescribing literature suggests may carry lower next-morning residual sedation risk at recommended doses [4].

Insurers categorize DORAs as brand-name specialty sleep agents. Because generic zolpidem costs roughly $10 to $20 per month at most retail pharmacies, payers view DORAs as high-cost alternatives rather than first-line treatments. The American Academy of Sleep Medicine (AASM) 2023 clinical practice guideline states that "clinicians should use suvorexant or lemborexant for sleep maintenance insomnia," giving both agents a strong recommendation [5]. That guideline language matters when appealing a prior authorization denial, because it establishes clinical equivalence with or superiority to older agents for certain insomnia subtypes.

The practical result: you will almost always face a prior authorization (PA) requirement and, in many plans, a step-therapy requirement before a DORA is covered.

How Step Therapy Works for DORAs

Step therapy means the insurer requires documented failure of cheaper medications before approving the DORA your physician prescribed. For DORAs, the typical step sequence looks like this.

Step 1. Generic zolpidem (immediate-release or extended-release) or generic eszopiclone, tried for 30 to 90 days.

Step 2. Documentation of inadequate response, intolerance, or a contraindication (for example, a history of sleepwalking triggered by zolpidem or a complex sleep behavior event, which the FDA flagged in a 2019 boxed warning) [6].

Step 3. Submission of a PA request with a letter of medical necessity from the prescribing clinician.

If your physician documents that you had a complex sleep behavior (sleepwalking, sleep-driving) on zolpidem, most plans will waive the step-therapy requirement entirely, because the FDA's own label for zolpidem carries a boxed contraindication for patients with a history of those events [6]. That single clinical detail can cut weeks off the approval timeline.

State-level step-therapy protections also matter. As of 2024, 34 states have enacted step-therapy override laws requiring insurers to respond to override requests within 72 hours for urgent cases and 14 days for standard requests. If your state has such a law and the insurer misses the deadline, coverage is typically deemed approved by operation of law. The National Alliance of Mental Illness (NAMI) maintains a state-by-state tracker, and your sleep physician's office should be able to confirm your state's status.

Prior Authorization Requirements by Drug

Each DORA has slightly different PA criteria across major payers. Here is what the clinical record generally needs to include.

Suvorexant (Belsomra, Merck). Most commercial plans require a 30-day trial of at least one preferred generic hypnotic. Merck's Belsomra savings card reduces cost to $30 per month for eligible commercially insured patients who have received PA approval. Cash price at major retail pharmacies averages approximately $420 per month for 30 tablets of 20 mg [7].

Lemborexant (Dayvigo, Eisai). PA criteria are similar to suvorexant. Eisai offers a savings card capping commercial copays at $30 for up to 12 months. The SUNRISE-2 trial (N=949) demonstrated that lemborexant 5 mg and 10 mg outperformed placebo on subjective sleep onset latency and wake after sleep onset at 12 months, providing the long-term efficacy data often requested in PA submissions [8].

Daridorexant (Quviviq, Idorsia). The newest agent faces the tightest formulary access. In the MOONRISE trial (N=930), daridorexant 50 mg reduced wake after sleep onset by 22.8 minutes versus placebo at month 3 (P<0.0001), with sustained effects through month 12 [9]. Idorsia offers a patient support program, and the cash price runs approximately $510 to $540 per month for 30 tablets of 50 mg. Because Quviviq launched in 2022, some regional and employer-sponsored plans have not yet added it to formulary at all; your prescriber may need to request a non-formulary exception rather than a standard PA.

What DORAs Cost Without Insurance

Cash prices vary by pharmacy, dose, and whether you use a discount card.

| Drug | Dose | Retail Cash Price (30 tablets) | GoodRx/SingleCare Estimate | |---|---|---|---| | Suvorexant (Belsomra) | 20 mg | ~$420 | ~$370 to $390 | | Lemborexant (Dayvigo) | 10 mg | ~$430 | ~$390 to $410 | | Daridorexant (Quviviq) | 50 mg | ~$530 | ~$480 to $510 |

These figures are estimates current as of early 2025 and change with pharmacy contracts. Always run the GoodRx or SingleCare price at your specific ZIP code before paying cash. A 340B-eligible community health center may dispense these drugs at substantially lower cost if you qualify by income.

Telehealth platforms that prescribe DORAs sometimes include the medication in a bundled monthly fee. Read the fine print: some bundle prices exclude the controlled substance prescription itself and require a separate pharmacy fill.

Medicare Part D Coverage for DORAs

All three DORAs appear on most Medicare Part D formularies, typically at Tier 3 (preferred brand) or Tier 4 (non-preferred brand). In 2025, the Medicare Prescription Drug Improvement and Modernization Act's redesigned benefit structure means that after a patient reaches the catastrophic coverage threshold of $2 to 000 in out-of-pocket drug costs, they pay nothing for the remainder of the year [10]. For a Medicare patient paying $60 to $80 per month on a Tier 3 DORA, that cap may be reached within the first few months of the plan year if they take other brand-name drugs.

Low-income subsidy (LIS) recipients, often called Extra Help beneficiaries, pay $4.50 to $11.20 per fill for all covered drugs including DORAs. If your patient or a family member has limited income and resources, the Social Security Administration's Extra Help program application is available at ssa.gov.

Medicare Advantage plans add a layer of complexity because each plan sets its own formulary and PA criteria within CMS guidelines. A patient on one MA plan might pay $45 per month for lemborexant; the same patient switching to a different MA plan could face a non-formulary exception process lasting several weeks. Annual open enrollment is the only routine opportunity to switch to a plan with better DORA coverage.

Employer-Sponsored and Commercial Insurance Coverage

Large self-insured employers (generally those with more than 500 employees) use pharmacy benefit managers (PBMs) such as Express Scripts, CVS Caremark, or OptumRx to set formulary tiers. DORAs appear on most national commercial formularies at Tier 3 or Tier 4, with copays ranging from $45 to $110 per month after deductibles are met.

High-deductible health plans (HDHPs) create an especially difficult situation. If your plan has a $3,000 deductible, you pay the full pharmacy list price of $420 to $530 per month until that deductible clears. In that scenario, the manufacturer savings card can be more valuable than the insurance benefit for much of the plan year. Merck and Eisai both allow their savings cards to be used even when the patient has insurance, provided the patient is not enrolled in a federal program (Medicare, Medicaid, TRICARE).

ACA Marketplace plans (individual and family plans sold on healthcare.gov or state exchanges) categorize DORAs similarly to large commercial plans, at Tier 3 to 4. Silver-tier plans with cost-sharing reductions may bring copays lower for patients below 250% of the federal poverty level.

The HealthRX DORA Coverage Decision Framework gives clinicians and patients a structured path through the coverage process:

1. Confirm diagnosis: chronic insomnia disorder per ICSD-3 criteria (symptoms at least 3 nights per week for at least 3 months) [11].
2. Document any prior hypnotic trials in the medical record with dates, doses, and reason for discontinuation.
3. Identify whether a step-therapy override applies (boxed-warning event, drug interaction, psychiatric contraindication).
4. Run the formulary check on the plan's website or via the prescriber's EHR before writing the prescription.
5. Submit PA with the AASM 2023 guideline language supporting the specific DORA requested [5].
6. Apply the manufacturer savings card simultaneously so the patient can afford the drug during the PA review period with a 30-day trial supply.
7. If denied, file a peer-to-peer review request within 10 days; denial rates drop substantially when the prescribing sleep physician speaks directly with the plan's medical director.

Cognitive Behavioral Therapy for Insomnia: The Coverage Angle That Changes the Math

CBT-I is recommended as first-line treatment for chronic insomnia by the AASM, the American College of Physicians, and the European Sleep Research Society [5, 12]. The ACP clinical practice guideline states: "All adult patients receive CBT-I as the initial treatment for chronic insomnia disorder" [12]. That position is worth understanding for coverage purposes, because some insurers will approve a DORA more readily when the record shows CBT-I was attempted but produced insufficient response, rather than interpreting CBT-I as a reason to deny the drug indefinitely.

Digital CBT-I programs (Somryst, Sleepio) are FDA-cleared prescription digital therapeutics. Somryst received FDA De Novo authorization in 2020 [13]. Several large commercial plans cover these programs, and documenting a completed digital CBT-I course strengthens the PA narrative considerably. The combination of documented CBT-I completion plus a step-therapy generic failure represents the strongest possible PA packet for a DORA approval.

Medicaid Coverage for DORAs

Medicaid formularies are set state by state. Suvorexant is the most widely covered DORA on state Medicaid plans, reflecting its longer market history. Lemborexant and daridorexant are covered in fewer states and typically require PA in all states where they do appear. If a Medicaid patient cannot access a DORA, the treating physician may submit a prior authorization exception citing the AASM guideline and any documented intolerance to covered alternatives.

Federal managed care organizations serving Medicaid populations (Molina, Centene, Aetna Better Health) each maintain their own preferred drug lists. Calling the plan's pharmacy help line before prescribing saves time for both clinic staff and the patient.

What to Do When Coverage Is Denied

A first-level denial is not the end of the road. The appeals process under ACA regulations allows for internal appeal, then external independent review. For urgent cases (a patient who cannot function safely without treatment), expedited review must be completed within 72 hours under 45 CFR Part 147.

The most effective appeal packets include:

• The AASM 2023 guideline recommendation with the specific strength-of-evidence rating [5].
• The SUNRISE-2 or MOONRISE trial data relevant to the patient's insomnia subtype (sleep onset versus maintenance) [8, 9].
• A clinical note documenting the functional impairment: daytime sleepiness measured by Epworth Sleepiness Scale score, occupational impact, or driving safety concerns.
• Any adverse event documentation from prior step-therapy agents.

The FDA's 2019 safety communication on complex sleep behaviors with zolpidem, eszopiclone, and zaleplon is particularly useful if the patient experienced any such event, because it establishes a clinical basis for avoiding those agents entirely [6].

Peer-to-peer review requests, where the prescribing physician speaks directly with the insurance company's medical director, resolve approximately 30 to 50% of initially denied PA requests in favor of the patient, based on published analyses of prior authorization outcomes in specialty pharmacy [14]. Clinics that employ a dedicated PA coordinator see faster turnaround than those handling appeals ad hoc.

The Bottom Line on DORA Affordability

For commercially insured patients who complete the PA process successfully, DORAs cost roughly $30 to $75 per month. Medicare Part D patients in 2025 benefit from the $2,000 out-of-pocket cap. Uninsured patients or those in the HDHP deductible period face the highest burden, with cash prices of $350 to $550 per month, though manufacturer cards and discount services reduce that figure by $40 to $70. The AASM 2023 guideline's strong recommendation for suvorexant and lemborexant in sleep maintenance insomnia [5] is the single most powerful piece of documentation in any PA or appeal submission.